Bhatti MM, Boonlayangoor S, Beavis KG, et al. Evaluation of FilmArray and Verigene systems for rapid identification of positive blood cultures. J Clin Microbiol. 2014;52:3433-3436.
Buchan BW, Windham S, Balada-Llasat JM, et al. Practical comparison of the BioFire FilmArray pneumonia panel to routine diagnostic methods and potential impact on antimicrobial stewardship in adult hospitalized patients with lower respiratory tract infections. J Clin Microbiol. 2020;58:e00135-20.
FDA.gov. Nucleic acid based tests. Accessed March 5, 2021. https://www.fda.gov/medical-devices/vitro-diagnostics/nucleic-acid-based-tests#microbial
FDA.gov. Evaluation of automatic class III designation for Unyvero LRT Application and Unyvero System: decision summary. Accessed March 5, 2021. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170047.pdf
FDA.gov. Biofire Filmarray marketing approval. May 17, 2018. Accessed March 5, 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf18/K181324.pdf
Fu Y, Yang Q, Xu M, et al. Secondary bacterial infections in critical ill patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7:ofaa220.
IDSA Sepsis Task Force. Infectious Diseases Society of America (IDSA) Position Statement. Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clin Infect Dis. 2018;66:1631-1635.
Kerr KH, Vyas NM, Hou C, et al. Clinical and pharmacoeconomic impact of rapid diagnostic pneumonia panel in critically ill patients admitted with nosocomial pneumonia. Open Forum Infect Dis. 2020;7(S1):Abstract 98.
Klompas M, Calandra T, Singer M. Antibiotics for sepsis - finding the equilibrium. JAMA. 2018;320:1433-1434.
Kollef MH, Burnham JP. Antibiotic thresholds for sepsis and septic shock. Clin Infect Dis. 2019;69:938-940.
Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Crit Care Med. 2018;46:997-1000.
Luyt CE, Bréchot N, Trouillet JL, Chastre J. Antibiotic stewardship in the intensive care unit. Crit Care. 2014;18:480.
Marik PE, Farkas JD, Spiegel R, et al. POINT: Should the Surviving Sepsis Campaign Guidelines be retired? Yes. Chest. 2019;155:12-14.
Messacar K, Parker SK, Todd JK, et al. Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship. J Clin Microbiol. 2017;55:715-723.
Rhee C, Filbin MR, Massaro AF, et al. Compliance with the National SEP-1 Quality Measure and association with sepsis outcomes: a multicenter retrospective cohort study. Crit Care Med. 2018;46:1585-1591.
Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6:791.
Spiegel R, Farkas JD, Rola P, et al. The 2018 Surviving Sepsis Campaign's Treatment Bundle: When guidelines outpace the evidence supporting their use. Ann Emerg Med. 2019;73:356-358.
Timbrook TT, Morton JB, McConeghy KW, et al. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:15-23.
Wunderink RG, Srinivasan A, Barie PS, et al Antibiotic stewardship in the intensive care unit. An Official American Thoracic Society Workshop Report in Collaboration with the AACN, CHEST, CDC, and SCCM. Ann Am Thorac Soc. 2020;17:531-540.

As organizations accredited by the ACCME, the Society of Critical Care Medicine (SCCM) and Medscape, LLC require everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Debra Goff, PharmD, FIDSA, FCCP

Professor of Pharmacy Practice
OSU College of Pharmacy
Infectious Diseases Specialist
The Ohio State University
Wexner Medical Center
Columbus, Ohio

Disclosures

Disclosure: Debra A. Goff, PharmD, FIDSA, FCCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: CARBx; Opgen
Received grants for clinical research from: Merck; Pfizer

Edward J. Septimus, MD, FIDSA, FACP

Professor of Internal Medicine
Texas A&M College of Medicine
Houston, Texas

Disclosures

Disclosure: Edward J. Septimus, MD, FIDSA, FACP, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: BioMérieux

Trevor Van Schooneveld, MD, FACP

Associate Professor of Infectious Disease
Medical Director
Antimicrobial Stewardship Program
University of Nebraska College of Medicine
Omaha, Nebraska

Disclosures

Disclosure: Trevor Van Schooneveld, MD, FACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BioFire

Editor

Maria B. Uravich, BSc

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Maria B. Uravich, BSc, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CME / CE

SPOTLIGHT: Critical Care Updates 2021: The Latest Advances in Diagnosing Sepsis and Pneumonia

Authors: Debra A. Goff, PharmD, FIDSA, FCCP; Edward J. Septimus, MD, FIDSA, FACP; Trevor Van Schooneveld, MD, FACP
CME / CE Released: 4/21/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/21/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for critical care specialists, pulmonologists, intensivists, hospitalists, infectious disease specialists, and all members of the multidisciplinary team involved in the care for patients who have or are at risk for pneumonia and sepsis.

The goal of this activity is to improve clinicians' ability to make a timely and accurate diagnosis for patients with pneumonia and sepsis.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest updates and advances in available technologies for the rapid diagnosis of sepsis and pneumonia
Demonstrate improved competence associated with
- The timely and appropriate utilization of rapid technologies to establish a diagnosis of sepsis and/or pneumonia
- Clinicians' ability to accurately interpret the results of rapid tests to inform clinical decision-making in the treatment of sepsis and pneumonia
Demonstrate greater confidence in their ability to
- Foster development of best practices for the implementation of antibiotic stewardship strategies in the management of sepsis and pneumonia

Disclosures

Faculty

Debra Goff, PharmD, FIDSA, FCCP

Professor of Pharmacy Practice
OSU College of Pharmacy
Infectious Diseases Specialist
The Ohio State University
Wexner Medical Center
Columbus, Ohio

Disclosures

Disclosure: Debra A. Goff, PharmD, FIDSA, FCCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: CARBx; Opgen
Received grants for clinical research from: Merck; Pfizer

Edward J. Septimus, MD, FIDSA, FACP

Professor of Internal Medicine
Texas A&M College of Medicine
Houston, Texas

Disclosures

Disclosure: Edward J. Septimus, MD, FIDSA, FACP, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: BioMérieux

Trevor Van Schooneveld, MD, FACP

Associate Professor of Infectious Disease
Medical Director
Antimicrobial Stewardship Program
University of Nebraska College of Medicine
Omaha, Nebraska

Disclosures

Disclosure: Trevor Van Schooneveld, MD, FACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BioFire

Editor

Maria B. Uravich, BSc

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Maria B. Uravich, BSc, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

Presented through a collaboration between Society of Critical Care Medicine (SCCM) and Medscape Education.

The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.

The Society of Critical Care Medicine (SCCM) is accredited by the ACCME to provide continuing medical education for physicians.

For Physicians

The Society of Critical Care Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

For Nurses

The Society of Critical Care Medicine (SCCM) is approved by the California Board of Registered Nursing, Provider No. 8181, for 0.5 contact hours.

For Pharmacists

The Society of Critical Care Medicine (SCCM) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity will provide 0.5 continuing education hours. ((0236-9999-21-110-H01-P) For questions, contact SCCM at [email protected] or call 1-847-827-6869.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures
Study the educational content online or print it out.
Click the Earn Credit button to visit www.sccm.org/Education-Center/On-Demand/Advances-in-Diagnosis-Sepsis-and-Pneumonia, and log in using your existing SCCM Customer ID or follow the steps to create a new account.

*The credit that you receive is based on your user profile.

From Medscape Education Infectious Diseases

CME / CE

SPOTLIGHT: Critical Care Updates 2021: The Latest Advances in Diagnosing Sepsis and Pneumonia

Authors: Debra A. Goff, PharmD, FIDSA, FCCP; Edward J. Septimus, MD, FIDSA, FACP; Trevor Van Schooneveld, MD, FACPFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 4/21/2021

Valid for credit through: 4/21/2022, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to improve clinicians' ability to make a timely and accurate diagnosis for patients with pneumonia and sepsis.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / CE Information Download Slides

Full Live Event Audio

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Debra Goff, PharmD, FIDSA, FCCP

Edward J. Septimus, MD, FIDSA, FACP

Trevor Van Schooneveld, MD, FACP

Editor

Maria B. Uravich, BSc

Content Reviewer

Esther Nyarko, PharmD

CME / CE

SPOTLIGHT: Critical Care Updates 2021: The Latest Advances in Diagnosing Sepsis and Pneumonia

Target Audience and Goal Statement

Disclosures

Faculty

Debra Goff, PharmD, FIDSA, FCCP

Edward J. Septimus, MD, FIDSA, FACP

Trevor Van Schooneveld, MD, FACP

Editor

Maria B. Uravich, BSc

Content Reviewer

Esther Nyarko, PharmD

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

SPOTLIGHT: Critical Care Updates 2021: The Latest Advances in Diagnosing Sepsis and Pneumonia

Educational Impact Challenge